ABC News/Good Morning America – Feb. 28
Dr. Robert Wenham, chair of Moffitt’s Gynecological Oncology, told "GMA" that while Kenni's condition is "very, very rare" it can still happen. "Among all ages combined, Ovarian Germ Cell Tumors 'GCTs' [which includes yolk-sac tumors] make up about one in four ovarian tumors in all ages with about one in five of those tumors being cancerous, and only one in five of those being yolk-sac tumors," Wenham said.
The Daily Mail – Feb. 28
'This is very, very rare,' Dr Robert Wenham, Chair of Moffitt Cancer Center's Gynecological Oncology Department told DailyMail.com, adding: 'It is the youngest of which I have heard.'
Everyday Health – Feb. 27
Researchers from the NYU School of Medicine and Moffitt Cancer Center surveyed 450 oncologists from 45 NCI-designated cancer centers around the United States to gauge their level of knowledge with regard to treating people who identify as lesbian, gay, bisexual, or transgender, as well as their attitude, behavior, and willingness to learn more about serving this community.
Laker/Lutz News – Feb. 27
In addition to the state college, community partners involved in the summit included the National Alliance on Mental Illness, Pasco Alliance for Substance Abuse Prevention, BayCare Behavioral Health – Community Health Activation Team (CHAT), American Foundation for Suicide Prevention, Take Stock in Children, James A. Haley Veterans Hospital, Moffitt Cancer Center and Pasco Aware.
Tampa Bay Times – Feb. 27
Nearly 12 percent of the U.S. population identifies as lesbian, gay, bisexual or transgender. But the LGBTQ community has long been underserved when it comes to health care, a new study by researchers at Tampa-based Moffitt Cancer Center concludes.
Targeted Oncology – Feb. 26
In an interview with Targeted Oncology during the 2019 TCT meeting, Locke, medical director and research director of the Immune Cell Therapy Program and the co-program leader of the Immunology Program, vice chair of the Blood and Marrow Transplant and Cellular Immunotherapy program at Moffitt Cancer Center, discussed the optimal management of CAR T-cell therapy-related AEs.
Science Daily – Feb. 26
Andersen conducted the study with Claire Conley, a former Ohio State graduate student now at the H. Lee Moffitt Cancer Center in Tampa. Their results appear in the March 2019 issue of the journal Health Psychology.
Medscape – Feb. 26
Presenter Joseph A. Pidala, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, said that the reduction in treatment failure rate vs benchmark data was "notable" given that the historical data came from patients who had received fewer prior treatments.
Oncology Nursing News – Feb. 25
CAR T-cell therapy is changing the treatment landscape for patients with blood cancers, inducing durable responses in patients with lymphoma who did not respond to chemotherapy, explained Frederick Locke, MD.
AARP – Feb. 25
Dr. Robert Keenan uses Telehealth, consulting with patients via video camera and computer at Moffitt Cancer Center in Tampa, FL.
OncLive – Feb. 25
We have been very interested in immunotherapy. The KEYNOTE-158 study was presented by Jonathan Strosberg, MD, of Moffitt Cancer Center, at the 2019 Gastrointestinal Cancers Symposium; those data were a little discouraging.
Tampa Bay Times – Feb. 22
Vycellix, which works to create new cell- and gene-based cancer therapies, will start in April to the University Park Business Center on E Fowler Avenue, near the H. Lee Moffitt Cancer Center & Research Institute.
Cancer Network – Feb. 22
“Radiomics appears to offer a nearly limitless supply of imaging biomarkers that could potentially aid cancer detection, diagnosis, assessment of prognosis, prediction of response to treatment, and monitoring of disease status,” wrote several experts led by Robert J. Gillies, PhD, of the department of cancer imaging at the H. Lee Moffitt Cancer Center in Tampa, Florida, in 2015.
OncLive – Feb. 22
In an interview with OncLive during the 2019 TCT meeting, Locke, medical director and research director of the Immune Cell Therapy Program and the co-program leader of the Immunology Program, vice chair of the Blood and Marrow Transplant and Cellular Immunotherapy program at Moffitt Cancer Center, discussed the optimal management of CAR T-cell therapy-related AEs.
Medium – Feb. 22
The analysis of these massive amounts of digital data can discover things invisible to the naked eye, according to Marilyn Bui, MD, PhD, president of the Digital Pathology Association and a pathologist, lab director, and program director at the Moffitt Cancer Center.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.